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Simple Summary: Ewing sarcoma is an aggressive tumor with still unacceptable survival rates,
particularly in patients with metastatic disease and for which it is necessary to develop new and
innovative therapies. These tumors are characterized by the presence of chromosomal translocations
that give rise to chimeric transcription factors (i.e., EWSR1–FLI1) that govern the oncogenic process.
In this article, we describe an efficient strategy to permanently inactivate the EWSR1–FLI1 oncogene
characteristic of Ewing sarcoma using CRISPR/Cas9 gene editing technology. Although the appli-
cation of gene therapy in cancer still has many limitations, for example, the strategy for delivery,
studies like ours show that gene therapy can be a promising alternative, particularly for those tumors
that are highly dependent on a particular oncogene as is the case in Ewing sarcoma.
Abstract: Ewing sarcoma is an aggressive bone cancer affecting children and young adults. The
main molecular hallmark of Ewing sarcoma are chromosomal translocations that produce chimeric
oncogenic transcription factors, the most frequent of which is the aberrant transcription factor
EWSR1–FLI1. Because this is the principal oncogenic driver of Ewing sarcoma, its inactivation should
be the best therapeutic strategy to block tumor growth. In this study, we genetically inactivated
EWSR1–FLI1 using CRISPR-Cas9 technology in order to cause permanent gene inactivation. We
found that gene editing at the exon 9 of FLI1 was able to block cell proliferation drastically and induce
senescence massively in the well-studied Ewing sarcoma cell line A673. In comparison with an
extensively used cellular model of EWSR1–FLI1 knockdown (A673/TR/shEF), genetic inactivation
was more effective, particularly in its capability to block cell proliferation. In summary, genetic
inactivation of EWSR1–FLI1 in A673 Ewing sarcoma cells blocks cell proliferation and induces
a senescence phenotype that could be exploited therapeutically. Although efficient and specific
in vivo CRISPR-Cas9 editing still presents many challenges today, our data suggest that complete
inactivation of EWSR1–FLI1 at the cell level should be considered a therapeutic approach to develop
in the future.
Keywords: Ewing sarcoma; EWSR1–FLI1; CRISPR/Cas9; gene therapy; cell cycle arrest; senescence
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1. Introduction
Ewing sarcoma is a highly aggressive rare bone and soft tissue tumor arising in
children and young adults [1]. Despite international collaborative efforts to improve Ewing
sarcoma outcome [2–4], overall survival rates for patients with localized disease have
remained stagnant at approximately 65–70% for decades, and the situation is especially
frustrating for relapsed patients whose prognosis is certainly fatal [5]. Hence, it is necessary
to identify innovative therapies that represent a real breakthrough in treating this disease.
The biology of Ewing sarcoma is relatively well known. From a molecular perspective,
Ewing sarcoma is characterized by reciprocal chromosomal translocations that give rise to
fusion proteins that govern tumorigenesis [1]. The most frequent of these fusions proteins is
EWSR1–FLI1 in which the N-terminal region of the EWSR1 gene is fused to the C-terminal
region of the transcription factor FLI1 containing the DNA binding domain [6]. EWSR1–
FLI1 results from the chromosomal translocation t(11;22), present in nearly 85% of Ewing
sarcoma tumors. The remaining tumors harbor other functionally equivalent chromosomal
translocations involving other transcription factors (i.e., ERG, FEV) and other EWSR1-
related proteins (i.e., FUS) [1]. In contrast, other chromosomal aberrations are rare and
point mutations affecting oncogenes or tumor suppressor genes are even less frequent [7,8].
In light of this data, it is thoroughly accepted that these chimeric transcription factors are
the main oncogenic drivers in Ewing sarcoma [1].
Experimental data accumulated over the last 20 years have demonstrated that EWSR1–
FLI1 plays a central role in Ewing sarcoma pathogenesis. As an aberrant transcription factor,
EWSR1–FLI1 dictates a specific transcriptional program that promotes cell proliferation
and blocks cell differentiation [9,10]. Several direct and indirect EWSR1–FLI1 targets
contributing to this transcriptional program have been identified, and functional studies
have corroborated its individual contribution to cancer pathogenesis [11–15]. In addition,
EWSR1–FLI1 also contributes to defining an epigenetic program in Ewing sarcoma cells
that also contributes to the oncogenic profile [16–18]. Nevertheless, the most relevant
data demonstrating the critical role of EWSR1–FLI1 in Ewing sarcoma pathogenesis comes
from functional studies carried out in Ewing sarcoma cell models in which EWSR1–FLI1
expression has been knocked-down using RNA interference approaches. Those studies
have shown that EWSR1–FLI1 knockdown impairs proliferation of Ewing sarcoma cells
both in vitro and in vivo, reinforcing the idea that EWSR1–FLI1 targeted inactivation
should be the most effective therapy against Ewing sarcoma [19].
The discovery of the CRISPR/Cas9 system in bacteria and its rapid incorporation
into laboratories as a tool for biochemical and genetic manipulation has definitively
changed the way research is conducted and has opened a wide range of therapeutic
opportunities [20–22]. Cas9 is a nuclease that produces double-stranded breaks (DSBs) at
specific DNA localizations guided by an RNA sequence targeting a particular region [23].
The guide RNA has minimal requirements, the most important of which is a sequence
located in the DNA, immediately juxtaposed to the sequence recognized by the RNA
guide, called protospacer adjacent motif (PAM). Since PAM sequences range from 2 to
8 nucleotides depending on each nuclease, several possible guide RNAs can be located in
a determined gene [24]. The efficiency of Cas9-mediated DSBs depends on the specific re-
quirements of the guide RNA sequence, some of which have been identified [25]. However,
determining the specificity and efficiency of a particular guide RNA can ultimately only be
assessed experimentally.
If a donor DNA accompanies Cas9 and guide RNA, the DNA target sequence will
be modified according to this donor DNA thanks to the homology-directed repair (HDR)
system present in the cells. The HDR system will repair the double-stranded breaks
produced by the Cas9 nuclease using the donor DNA as a template. However, the primary
autonomous cell system involved in repairing the DSBs generated by Cas9 is the non-
homologous end joining (NHEJ). According to this mechanism, DNA ends are directly
ligated without the need for a homologous template. This DNA repairing pathway is
error-prone, generating short deletions or insertions and a defective repair of DNA double-
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strand breaks. If this happens in coding DNA, it will produce frameshift mutations
and, consequently, premature stop codons and non-functional proteins. The easiness of
producing null alleles using CRISPR libraries has been utilized to identify essential genes
in cancer cell lines targeting hundreds of thousands of genes [26–28], to produce more
easily loss of function animal models [29], or to inactivate oncogenes in human cancer cells
both in vitro and in vivo [30,31].
In this study, we used CRISPR/Cas9 technology to inactivate genetically the more
frequent fusion gene in Ewing sarcoma, EWSR1–FLI1, and analyzed the cellular and
molecular implications of gene inactivation in comparison to gene silencing. We identified,
experimentally, a guide RNA that specifically and efficiently targets the EWSR1–FLI1 gene
and demonstrate that this strategy produces full cell cycle arrest and senescence that could
be exploited therapeutically.
2. Materials and Methods
2.1. Cell Lines
The Ewing sarcoma cell lines A673 (CRL-1598) were purchased from American Type
Culture Collection (Manassas, VA, USA) and maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 50 U/mL penicillin,
and 50 µg/mL streptomycin. The A673/TR/shEF cells, which express a specific shRNA
inducible by doxycycline directed against EWSR1–FLI1 mRNA, have previously been
described in detail [12]. The A673/TR/shEF cells were maintained in DMEM supplemented
with 10% tetracycline-free FBS (Capricorn Scientific, Ebsdorfergrund, Germany), 50 U/mL
penicillin, 50 µg/mL streptomycin, 100 µg/mL zeocin, and 3 µg/mL blasticidin. The
A673/TR/shEF cells were stimulated with doxycycline (1 µg/mL) to induce the expression
of EWSR1–FLI1-specific shRNA.
2.2. Establishment of A673 Cells Expressing Cas9 Protein and sgRNAs
The A673 cells were infected with lentiviral particles carrying CP-LvC9NU-02 vector
(Genecopoeia, Rockville, MD, USA) encoding Cas9 and GFP under the CMV and SV40
promoters, respectively. Cells were infected using two different (2.5 and 5) multiplicity of
infection (MOI) and selected with G418 (500 µg/mL). Clonal cell populations were obtained
by the dilution limit method. Cas9 expression levels were analyzed with an anti-Cas9
specific antibody (#Ab191468, AbCam, Cambridge, UK) by Western blot. The A673/Cas9
clones with constitutive expression of Cas9 were infected with lentiviral particles containing
sgRNAs lentiviral expression vectors (see below) using an MOI of 1 or 5. Cells were
selected with hygromycin (350 µg/mL) and cultivated for at least 50 days in the same
conditions. Three different experiments with independent sgRNAs lentiviral infections
were performed.
2.3. Selection of the Best Guide RNA (sgRNA) to Target EWSR1–FLI1
The A673 cells were infected with a commercial CRISPR library of 18,479 different
sgRNAs targeting 1983 transcription factors including ten gRNAs located in the FLI1 gene
(Supplementary Materials, Table S1) (#CB-11257, Thermo Fisher Scientific, Waltham, MA,
USA). Two independent experiments were performed. In each experiment, a total of
150 × 106 cells were infected at an MOI of 0.22 to obtain near 90% of cells infected with a
unique sgRNA and a minimal representativeness of 500 cells per sgRNA. After 24 h, DNA
was extracted for several plates and stored as control DNA. The remaining plates were then
maintained in standard culture medium supplemented with puromycin (1 µg/mL) for
25 days, and then DNA was also extracted. Next, at least 27 µg of DNA from control and
experimental conditions were PCR amplified with primers U6Primer-F (GGACTATCATAT-
GCTTACCGTA) and Lenti-gRNA-R2 (TTCAAGTTGATAACGGACTAGC) which were
located to both sides of each guide sequence. The PCR reactions were pooled, purified,
indexed, and sequenced 1 × 150 in a NextSeq500 sequencer (Illumina, San Diego, CA,
USA). At least 13 × 106 reads were obtained per condition and experiment. The resulting
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Fastq files were processed in the web-based platform Galaxy [32] (relevant parameters
are indicated in parentheses). First, Fastq files were trimmed with “Trim sequences” to
extract the sequences exclusively corresponding to guide RNAs. Next, quality control
was performed with FastQC, and reads with low average quality reads were filtered-out
with “Trimmomatic” (AVGQUAL ≥ 25). Filtered-in reads were mapped against the guide
sequences provided by the manufacturer using “BWA” (default parameters). Afterwards,
“IdxStats” was used on BAM files generated in the previous step to quantify the number of
reads for each guide (counts). Finally, data were exported to Excel spreadsheets and counts
per each gRNA normalized by the total of counts in the experiment. This normalized value
was compared between experimental and control conditions to calculate the enrichment
score observed per gRNA. Selected gRNAs were cloned into lentiviral expression vectors
to produce active sgRNAs in A673-infected cells (VectorBuilder, Chicago, IL, USA).
2.4. Cell Proliferation Assay
Cumulative population doubling was determined from cells maintained over 40–50 days
in continuous growth. Cells were seeded at a density of 2.5 × 105 cells in 100 mm plates.
Before reaching confluence (80–90%), cells were trypsinized, and the number of viable cells
was determined using trypan blue solution (NanoEnTek Inc., Seoul, Korea) and an EVE™
automatic cell counter (NanoEnTek Inc., Seoul, Korea). Afterwards, a fraction of the cells
was seeded again at the same cell density, and the process was repeated until the end of the
experiment. At several time points, the remaining cells were analyzed by flow cytometry
or aliquoted, pelleted, and stored at −80 ◦C until DNA, RNA, or protein isolation was
performed. The number of population doublings was calculated with the formula: n◦ of
population doublings = log2 (numbers of cells at the initial time/number of cells at the
final time). Cell doubling time was calculated in each cycle of cell seeding–trypsinization
as cell doubling time = time elapsed between cycles/n◦ cell population doubling observed
in this period of time.
2.5. DNA, RNA, and Protein Isolation
DNA, RNA, and total protein were isolated at different time points of the cell prolifer-
ation assay. At each time point, cells were trypsinized, washed with PBS, and distributed
in three tubes. Pellets were stored at −80 ◦C until use. Genomic DNA was isolated us-
ing the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). RNA was extracted using
TRI-REAGENT according to the manufacturer’s protocol (Sigma–Aldrich, Sant Louis, MI,
USA) and additionally purified using RNeasy Mini Elute Cleanup kit (Qiagen, Hilden,
Germany). Purified DNA and RNA were quantified using NanoDrop (Thermo Fisher
Scientifics, Waltham, MA, USA). Total protein was isolated directly from cell pellets lysed
in RIPA buffer (1× PBS, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate) supplemented
with a protease and phosphatase inhibitor cocktail (Roche, Basel, Switzerland). Protein
concentration was determined with the Pierce BCA™ protein assay kit (Thermo Fisher
Scientifics Waltham, MA, USA).
2.6. Confirmation of Gene Editing
DNA fragments covering the gRNA target were firstly amplified by PCR. Then,
amplicons were analyzed by Sanger sequencing or next generation sequencing (NGS). The
primer sequences used to amplify each region are described in Supplementary Materials
Table S2. Sanger electropherograms were analyzed with the ICE CRISPR analysis tool
(Synthego, Redwood City, CA, USA) to quantify, approximately, the percentage of indels
mutations. For NGS, PCR products were indexed following the manufacturer’s instructions
(New England Biolabs, Ipswich, MA, USA), purified, pooled, and sequenced in a MiSeq
sequencer (Illumina, San Diego, CA, USA) using a 2 × 250 paired read setting. The average
depth of coverage was 20,000× for each amplicon. The percentage of indels after Cas9-
mediated editing was determined using Mosaic Finder, a bioinformatic software developed
inhouse [33,34]. The Mosaic Finder pipeline integrates read mapping, normalization of
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read counts, mutation frequency calculation, and genome-editing efficiency statistics at
each position of the target region. Briefly, Mosaic Finder takes the Fastq files generated
by pair-end sequencing and generates consensus sequences by joining the corresponding
read pairs (forward and reverse). The repertoire of consensus sequences (allelic clusters)
represents the allelic diversity generated by the Cas9-mediated edition. These clusters
are then aligned against the sequence used as reference and are classified in allelic classes
based on the different type of the identified mutation (mismatch, insertion/deletion). The
frequency of each cluster are then calculated and plotted.
2.7. Off-Target Analysis Using T7 Endonuclease I Assay
The BreakingCas tool was used to identify putative off targets for gRNA sequences [35],
and gene editing at putative off-targets was analyzed using a T7 Endonuclease I assay
that recognizes and cleaves non-perfectly matched DNA. PCR products obtained from
genomic DNA were firstly purified using the QIAquick PCR Purification Kit (Qiagen,
Hilden, Germany) and then 200 ng of the purified DNA was denatured for 5 min to 95 ◦C
and afterwards allowed to align slowly using a first step consisting of a −2 ◦C/s ramp rate
from 95 to 85 ◦C and a second step consisting of a −0.1 ◦C/s ramp rate from 85 to 25 ◦C.
Next, 1 µL (10,000 UI/mL) of T7 Endonuclease I (#M0302, New England Biolabs, Ipswich,
MA, USA) were added to the re-annealed PCR products and incubated at 37 ◦C for 15 min.
The fragmented PCR products were analyzed by agarose electrophoresis, photographed,
and the percentage of nuclease-specific cleavage products quantified by densitometry (Fiji
software) [36].
2.8. Reverse Transcription and Quantitative PCR (RT-qPCR)
A Taqman RT-qPCR assay was used to quantify the steady-state mRNA levels of
EWSR1–FLI1, NR0B1, and TBP (used as a reference housekeeping gene) as described
previously [37]. The CD44 mRNA steady-state levels were quantified using the SYBR-Green
qPCR kit (Quantimix Easy Kit, #10606-4153, Biotools, Madrid, Spain). The PCR reactions
were run on a Rotor Gene 6000 thermocycler (Qiagen, Hilden, Germany). The cycle
threshold (Ct) for each gene and TBP was calculated using the RotorGene Software (v2.3.1).
The relative expression for each gene was calculated as 2−∆Ct, where ∆Ct = Ctgene − CtTBP.
Sequences of primers and TaqMan probes are shown in Supplementary Materials Table S3.
2.9. Western Blot
For the Western blot, 10–20 µg of total protein extracts was subjected to electrophoresis
on 4–15% polyacrylamide precast gels (Bio-Rad, Hercules, CA, USA) and blotted onto
0.2 µm PVDF membranes (Trans-Blot Turbo Mini, Bio-Rad, Hercules, CA, USA). Mem-
branes were blocked with 5% skimmed milk powder in Tween-Tris Buffered Saline (TTBS)
1× and subsequently incubated with the corresponding primary antibodies diluted in the
same buffer overnight at 4 ◦C. The next day, the membranes were washed in TTBS 1×,
incubated with the secondary HRP-conjugated antibody, and washed again. The mem-
branes were finally incubated with enhanced chemiluminescence (ECL) reactive (Merck
Millipore, Darmstadt, Germany) and photographed on a ChemiDoc XRS+ System (BioRad,
Hercules, CA, USA). Membranes were incubated sequentially with different antibodies
after incubation with stripping buffer (Tris-HCL 1 M pH 6.8, SDS 10%, β-Mercaptoethanol
0.7%) for 30 min at 65 ◦C. The primary antibodies used were anti-FLI1 1:250 (#133485
Abcam, Cambridge, UK), anti-DAX1(NR0B1) 1:1000 (2F4 clone) [38], anti-CD44 1:1000
(#ab51037, Abcam, Cambridge, UK), and anti-β tubulin HRP 1:10,000 (#ab185057, Abcam,
Cambridge, UK). Anti-mouse IgG (#sc-2055) and anti-rabbit IgG (#sc-2357) HRP-conjugated
were purchased from Santa Cruz Biotechnology.
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2.10. Immunocytochemical–Immunofluorescence (ICC/IF) Studies
The A673/Cas9/sgRNA and A673/sgRNA (control) cells were seeded on glass cover
slides. After 72 h, the growth medium was removed, and the cells were washed in PBS.
Then, cells were fixed and permeabilized for 15 min in ice-cold methanol. After, cells
were incubated for 1 h in blocking solution (BS; 5% Goat Serum (v/v) in PBS 1×), washed
with PBS twice, and incubated overnight at 4 ◦C with anti-FLI1 rabbit monoclonal anti-
body (1:700 in BS; ab133485, AbCam, Cambridge, UK). The next day, cells were washed
4 × 10 min with PBS and incubated for 1.5 h at room temperature with the secondary anti-
body (1:500; Goat anti-rabbit IgG-Alexa Fluor 594, Abcam, Cambridge, UK) supplemented
with 4% FBS. Cells were counterstained for 4 min with the nuclear stain 4,6-diamidino-2-
phenylindole (DAPI), washed 4 × 10 min with PBS, and mounted on slides using ProLong™
Gold antifade mounting medium (#P36934, Thermo Fisher Scientific, Waltham, MA, USA).
Cells were visualized in a fluorescence microscope (Leica, Wetzlar, Germany).
2.11. Cell Cycle Analysis by Flow Cytometry
Around one million cells were trypsinized, centrifugated, and resuspended in 400 µL
of PBS 1×. Then absolute ethanol was added for at least 1 h at 4 ◦C to fix cells. Next, cells
were washed with PBS 1× and centrifuged. The pellet was incubated at 37 ◦C for 30 min in
darkness in a solution containing 50 µg/mL propidium iodide and 100 µg/mL RNAase A
in PBS 1×. Cells were analyzed in a MACS Quant Analyzer 10 flow cytometer (Miltenyi
Biotec, Cologne, Germany), and the results were analyzed using FlowJo™ software (v.10.7.1,
De Novo Software, Pasadena, CA, USA).
2.12. Senescence Assay
To assess the senescence state of cells, β-galactosidase activity, a known characteristic
of senescent cells, was measured. The Senescence-β-Gal Staining Kit (Cell Signaling
Technology, Danver, MA, USA) was used according to the manufacturer’s protocol. Briefly,
cells were seeded by duplicate in a 6-multiwell plate to a density of 40,000–50,000 cells
per well for 48 h. Then, cells were washed with PBS 1× and fixed with a fixative solution
for 10–15 min at room temperature and washed with PBS 1× twice. Then, 1 mL of β-
Galactosidase Staining Solution, containing 1 mg/mL X-Gal, was added per well and
the plate incubated at 37 ◦C, for 24–48 h in a dry incubator. A total of 20 fields were
photographed per experimental condition under a microscope and β-galactosidase-positive
cells counted by two independent researchers and the percentage of positive cells versus
total cells calculated.
3. Results
3.1. Selection of Guide RNAs Targeting EWSR1–FLI1
We chose the cell line A673 as a model to analyze the effect of EWSR1–FLI1 gene
inactivation in Ewing sarcoma cells, since this cell line is probably the Ewing sarcoma cell
line more broadly used to study Ewing sarcoma pathogenesis, particularly with regard to
the mechanism of EWSR1–FLI1-mediated oncogenesis. To select specific gRNAs targeting
the EWSR1–FLI1 gene, we took advantage of the data generated from a multiplex CRISPR
screening assay targeting 1983 transcription factors (Figure 1a). This library includes ten
different gRNAs targeting four different exons of FLI1. We first infected A673 cells with
lentivirus containing a vector encoding Cas9 to generate a stable cell line (A673/Cas9)
(Supplementary Materials, Figure S1) and afterwards, we infected the A673/Cas9 cells
with the CRISPR library targeting the transcription factors. Cells were cultured in selection
medium for 25 days, and the enrichment scores for each gRNAs were obtained as described
in detail in Materials and Methods (Section 2). As shown in Figure 1b, the enrichment
scores for each gRNA targeting FLI1 were largely dependent on the location of the target
sequence. Thus, gRNAs targeting FLI1 exons 2 and 5 had enrichment scores near one or
greater, indicating that targeting these exons did not have an effect on cell viability. This
agrees with the fact that the FLI1 wild type is not expressed in Ewing sarcoma cells [12]
Cancers 2021, 13, 3783 7 of 19
and, therefore, targeting the exons of FLI1 that are not included in the EWSR1–FLI1 fusion
protein are expected to have no effect. However, gRNAs targeting exons 7 and 9 of
FLI1, which are included in the chimeric protein, showed a significant reduction in the
enrichment score values, confirming a deleterious effect in the A673 cells (Figure 1b).
In view of this data, we chose two gRNAs for experimental validation and additional
molecular and functional characterization. One of them was the gRNA located in exon
9, which had the most severe effect on cell proliferation. The other, which was one of
the gRNAs located in exon 2, did not affect cell viability and was used here as a negative
control (Supplementary Materials, Table S1).




Figure 1. Selection of gRNAs targeting EWSR1–FLI1 and analysis of gene editing evolution. (a) Experimental design: 
Ewing sarcoma cell line A673 expressing Cas9 protein (A673/Cas9) were generated by lentiviral infection. After clonal 
selection, A673/Cas9 cells were infected with a multiplex lentiviral CRISPR library of 18,479 different sgRNAs targeting 
1983 transcription factors including ten gRNAs targeting FLI1. After this screening phase, two gRNAs were selected for 
functional and molecular characterization. A673/Cas9 were infected with lentiviral sgRNAs to generate 
A673/Cas9/sgRNA cells and then maintained in continuous growth to assess gene editing, cell proliferation, senescence, 
and studies of mRNA and protein expression at different time points. A673/TR/shEF, which expresses a specific EWSR1–
FLI1 shRNA upon doxycycline stimulation, were cultured and analyzed in a similar way. The results obtained upon gene 
editing and gene silencing were then compared. (b) Schematic representation of native FLI1 and EWSR1–FLI1 fusion 
genes, location of FLI1 gRNAs, and enrichment scores obtained for each gRNA in the CRISPR screening assay (mean ± SD 
of two independent experiments). 
3.2. Effect of EWSR1–FLI1 Gene Editing on EWSR1–FLI1 Expression and EWSR1–FLI1 Targets 
Once gene editing on EWSR1–FLI1 was confirmed, we decided to assess its effect on 
EWSR1–FLI1 expression as well as on two surrogate markers of EWSR1–FLI1 activity: 
NR0B1 (DAX1), a gene regulated positively by EWSR1–FLI1 [11], and CD44, a gene reg-
ulated negatively by EWSR1–FLI1 [39] (unpublished results). We compared the effects 
observed in CRISPR/Cas9 edited cells with those observed in A673/TR/shEF upon 
doxycycline stimulation (gene silencing).  
As shown in Figure 2a, gene editing on FLI1 exon 2 had a negligible effect on 
EWSR1–FLI1 mRNA levels. Interestingly, gene editing on FLI1 exon 9 also had no effect 
on EWSR1–FLI1 mRNA levels. This suggests that although gene editing was verified by 
sequencing (Figures S2 and S3), it did not seem to affect the steady-state levels of 
EWSR1–FLI1 mRNA. As previously reported, the stimulation of A673/TR/shEF cells with 
doxycycline reduced the levels of EWSR1–FLI1 mRNA nearly 70% [11]. Figure 2a also 
shows the results regarding EWSR1–FLI1 gene targets NR0B1 and CD44. Gene editing on 
FLI1 exon 2 had no effect on NR0B1 and CD44 mRNA levels, suggesting that EWSR1–
Figure 1. Selection of gRNAs targeting E SR1–FLI1 and analysis of gene editing evolution. (a) Experi ental design:
i s r c ll line 673 expressing Cas9 protein (A673/ s ) r r t le ti ir l infecti . ft r l l
as9 cells r i f t it t ti
tr ri ti f t r i l i t t r ti I . ft r t i r i , t r l t f r
functional and molecular characterization. A673/Cas9 were infected with lentiviral sgRNAs to generate A673/Cas9/sgRNA
cells and then maintained in continuous growth to assess gene editing, cell proliferation, senescence, and studies of mRNA
and protein expression at different time points. A673/TR/shEF, which expresses a specific EWSR1–FLI1 shRNA upon
doxycycline stimulation, were cultured and analyzed in a similar way. The results obtained upon gene editing and gene
silencing were then compared. (b) Schematic representation of native FLI1 and EWSR1–FLI1 fusion genes, location of FLI1
gRNAs, and enrichment scores obtained for each gRNA in the CRISPR screening assay (mean ± SD of two independent
experiments).
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Both gRNAs were cloned into lentiviral vectors under the control of a U6 promoter
and afterwards used to infect A673/Cas9 cells. Then, cells were maintained in selection
medium over 40–50 days to assess the effect of EWSR1–FLI1 gene inactivation over time
(Supplementary Materials, Figures S2–S5). Cell proliferation assays, cell cycle analysis,
senescence analysis, and mRNA and protein expression studies were performed at different
time points (Figure 1a). The results were compared with those obtained in A673/TR/shEF
cells, a well-established EWSR1–FLI1 silencing model based on a doxycycline-inducible
shRNA system (A673/TR/shEF) [12]. This allowed us to compare the effects of the EWSR1–
FLI1 gene editing versus EWSR1–FLI1 gene silencing (Figure 1a).
3.2. Effect of EWSR1–FLI1 Gene Editing on EWSR1–FLI1 Expression and EWSR1–FLI1 Targets
Once gene editing on EWSR1–FLI1 was confirmed, we decided to assess its effect
on EWSR1–FLI1 expression as well as on two surrogate markers of EWSR1–FLI1 activ-
ity: NR0B1 (DAX1), a gene regulated positively by EWSR1–FLI1 [11], and CD44, a gene
regulated negatively by EWSR1–FLI1 [39] (unpublished results). We compared the ef-
fects observed in CRISPR/Cas9 edited cells with those observed in A673/TR/shEF upon
doxycycline stimulation (gene silencing).
As shown in Figure 2a, gene editing on FLI1 exon 2 had a negligible effect on EWSR1–
FLI1 mRNA levels. Interestingly, gene editing on FLI1 exon 9 also had no effect on
EWSR1–FLI1 mRNA levels. This suggests that although gene editing was verified by se-
quencing (Figures S2 and S3), it did not seem to affect the steady-state levels of EWSR1–FLI1
mRNA. As previously reported, the stimulation of A673/TR/shEF cells with doxycycline
reduced the levels of EWSR1–FLI1 mRNA nearly 70% [11]. Figure 2a also shows the results
regarding EWSR1–FLI1 gene targets NR0B1 and CD44. Gene editing on FLI1 exon 2 had no
effect on NR0B1 and CD44 mRNA levels, suggesting that EWSR1–FLI1 was not affected in
these cells. However, gene editing in exon 9 reduced the levels of NR0B1 dramatically until
almost undetectable levels and increased the levels of CD44 more than 60-fold, indicating
that although steady-state levels of EWSR1–FLI1 mRNA were unaltered, EWSR1–FLI1
protein was probably not produced or it was not functional. As expected, NR0B1 and
CD44 mRNA levels decreased and increased respectively upon EWSR1–FLI1 silencing in
A673/TR/shEF cells. In the case of NR0B1, the effect of gene editing on mRNA levels was
clearly more intense than that observed upon gene silencing.
To confirm the effect of gene editing at the protein level, we analyzed the levels of
EWSR1–FLI1, NR0B1, and CD44 by Western blot. As shown in Figure 2b, EWSR1–FLI1 and
NR0B1 protein levels were reduced until nearly undetectable levels in A673/Cas9/FLI1-
EX9 cells when compared to A673/TR/Cas9/FLI1-EX2 cells. In agreement with mRNA lev-
els, CD44 protein was upregulated in A673/Cas9/FLI1-EX9. Similar results were obtained
in A673/TR/shEF stimulated with doxycycline compared to unstimulated control cells.
Finally, we analyzed the expression of EWSR1–FLI1 by immunofluorescence in cell cul-
tures (Figure 2c). EWSR1–FLI1 was detected in the nucleus of control and A673/Cas9/FLI1-
EX2 cells but was undetectable in the majority of A673/Cas9/FLI1-EX9 cells. Taken to-
gether, these results demonstrate that gene editing of FLI1 at exon 9 was able to efficiently
knockout the EWSR1–FLI1 gene and, consequently, the expression of the corresponding protein.
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3.3. Effect of EWSR1–FLI1 Gene Inactivation on Cell Proliferation
Next, we analyzed the effect of EWSR1–FLI1 gene editing on cell proliferation by
quantification of the cumulative population doubling for 45–55 days (Figure 3a). Gene
editing on the FLI1 exon 9 (A673/Cas9/FLI1-EX9) resulted in a significant reduction in
proliferation compared to control cells (non-edited). By contrast, no effects on cell pro-
liferation were observed in the A673 cells edited on FLI1 exon 2 (A673/Cas9/FLI1-EX2)
compared to the control. Figure 3b shows the average of the population doubling time
calculated from three independent experiments over time. The cell doubling time at the
end of the experiment increased significantly in A673/Cas9/FLI1-EX9 cells (164.6 ± 25.0 h)
in comparison to the control or A673/Cas9/FLI1-EX2 cells (40.7 ± 6.8 h; p < 0001, two-
way ANOVA, Tukey’s post hoc). Interestingly, the effect of EWSR1–FLI1 gene editing
in A673/Cas9/FLI1-EX9 cells on cell proliferation was greater than that observed upon
EWSR1–FLI1 knockdown in A673/TR/shEF cells. As shown in Figure 3a, continuous
stimulation of these cells with doxycycline over 35 days significantly reduced the cumu-
lative population doubling and increased the cell doubling time but to a lesser extent
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than that observed in A673/Cas9/FLI1-EX9. These results suggest that inactivation of
EWSR1–FLI1 by gene editing was able to affect proliferation in a more severe way than
EWSR1–FLI1 silencing.
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The evolution of gene editing (Figure S3) correlated with the proliferation profile
observed. Thus, the higher percentages of gene editing on exon 9 observed at the end of the
experiment were associated with the higher cell doubling time. This fact is compatible with
a strong addiction of Ewing sarcoma cells to EWSR1–FLI1, an essential gene for these cells
and whose gene editing and subsequent inactivation result in blockage of cell proliferation.
To confirm the effect of EWSR1–FLI1 gene editing on cell proliferation, we analyzed the
different phases of cell cycle by flow cytometry. As shown in Figure 3c, A673/Cas9/FLI1-
EX9 cells showed a near-complete blockage of the cell cycle as evidenced by the fact that
more than 90% of cells were in the G1 phase. EWSR-FLI1 silencing in A673/TR/shEF
also produced a significant increase in the percentage of cells in the G1 phase (nearly
67%) in comparison to control cells (42%) but to a lesser extent than that observed in
A673/Cas9/FLI1-EX9. Taken together, these results demonstrate that EWSR1–FLI1 gene
inactivation by gene editing produces a practically complete blockage of cell proliferation.
3.4. EWSR1–FLI1 Inactivation Produces Generalized Senescence
The severe cell cycle arrest observed in A673/Cas9/FLI1-EX9 cells is compatible with a
senescence phenotype. Thus, we analyzed whether the EWSR1–FLI1 gene inactivation pro-
duced a senescent state in A673 cells. With that purpose, we analyzed the β-galactosidase
activity, an accepted surrogate marker of senescence [40]. As shown in Figure 4a, more
than 80% of A673/Cas9/FLI1-EX9 cells stained positively for β-galactosidase activity. By
contrast, less than 5% of cells were β-galactosidase positive in the control (A673/sgRNA)
and A673/Cas9/FLI1-EX2. The A673/Cas9/FLI1-EX9 cells displayed the typical mor-
phological characteristics of senescent cells such as a flattened aspect and a vacuolized
cytoplasm (Figure 4b). EWSR1–FLI1 knockdown in A673/TR/shEF also induced a senes-
cent phenotype, although at a much lower level in comparison to Cas9 edited cells on FLI1
exon 9 (Figure 4a).
To further characterize this phenotype, A673/Cas9/sgRNAs cells were seeded at
low density and cultured for 15 days to allow for the formation of colonies (Figure 4c).
Afterwards, colonies were selected based on their morphological appearance (senescent vs.
normal phenotype), picked-up, reseeded in 96-well plates, and cultured for an additional
15 days until the colony grew large enough to be able to extract DNA. DNA was afterwards
analyzed for gene editing using Sanger sequencing and the ICE CRISPR tool. All colonies
of A673/Cas9/FLI1-EX2 cells showed the characteristic phenotype of normal A673 cells
in culture. Out of ten selected colonies, seven expanded after reseeding, and all of them
showed gene editing in exon 2 of FLI1. By contrast, two types of colonies were clearly
recognizable in A673/Cas9/FLI1-EX9 cells; a few colonies had the typical appearance of
A673 cells, while the majority of the colonies displayed the aspect of senescent cells. The
only normal colony that was picked out expanded quickly after reseeding. Interestingly,
this colony showed no gene editing at all in FLI1 exon 9, which is compatible with a
wild-type EWSR1–FLI1 gene. In contrast, only two out of nine colonies with a senescent
phenotype grew after replanting. In this case, both colonies showed gene editing in exon
9 of FLI1. These results suggest that senescent colonies had more problems expanding
after trypsinization, confirming the deleterious effect caused by the genetic inactivation of
EWSR1–FLI1.
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4. Discussion
Despite international collaborative efforts to improve Ewing sarcoma’s outcome,
the progress made over the last decades has been rather limited [2–4]. High-intensity
chemotherapy regimens are the standard treatment for these patients, and although this
approach is effective and even curative in a significant proportion of patients with localized
tumors, the prognostic of patients with metastatic disease or late relapses is very poor, with
5 year overall survival figures below twenty five percent [5]. There is, therefore, a consensus
in the field that it is absolutely indispensable to identify new innovative strategies that
can represent a real advance in the disease’s treatment. These advances can only come by
focusing on the tumor biology.
The molecular hallmark of Ewing sarcoma is the presence of chromosomal transloca-
tions that give rise to chimeric transcriptional factors that act as potent oncogenes governing
the transformation process. The fact that these fusion proteins, such as EWSR1–FLI1, are the
initial event that trigger the oncogenic events, makes this tumor ideal for the development
of targeted therapies [19]. With this idea in mind, several groups have attempted to develop
drugs able to interfere with the transcriptional activity of EWSR1–FLI1 fusion proteins.
Among these drugs are trabectedin and its analogs [41,42], Mithramycin [43,44], and YK-4–
279 and derivatives [45,46]. Although these drugs have reached clinical testing, the results
obtained have been, at the moment, discouraging because of the elevated toxicity in some
cases [47] and for the intrinsic difficulty in targeting transcription factors with pharmaco-
logical approaches [48], not to mention that pharmacological inhibition of EWSR1–FLI1
could require the administration of a drug for prolonged periods to achieve a durable
response, as occurs in the case of tyrosine kinase inhibitors (for example, imatibib) [49].
This could lead to a decrease in the drug’s efficacy or the appearance of resistance in the
clinical setting [50]. Therefore, to obtain the best possible results, it would be desirable to
obtain a complete and long-lasting inactivation of EWSR1–FLI1.
One way to obtain the inactivation of a determined gene could be the use of gene
therapy strategies. Complete gene inactivation through a genetic approach was unthinkable
only a few years ago, as we did not have the proper tools to conduct it. However, thanks
to the discovery of the CRISPR/Cas9 system, new opportunities have emerged in gene
therapy applied to cancer [22,51]. Although gene therapy-based approaches for treating
cancer are still in their early stages, and they are not without hurdles, there is great interest
from academia and industry in the development of these new approaches, which indicates
that these therapies can be a reality in the medium and long term [26,51].
Effective gene therapy for cancer must address at least three critical issues. First, it
must pursue the inactivation of essential genes for tumor growth, both at the primary site
and, more importantly, at metastatic sites. Second, it must be specific for the gene(s) of
interest. Third, it must include a mechanism that allows for transportation of the gene
editing machinery. In this work, we aimed to answer the first two questions in the context
of Ewing sarcoma. The next step will therefore be to develop a type of nanotherapy that
allows for transporting the gene editing machinery specifically to Ewing sarcoma cells, for
which it will be necessary not only to develop the vehicle itself but to design the elements
that allow the specific identification of target cells. The development of this methodology
will make it possible to analyze the efficacy of this therapy in preclinical models (e.g.,
growth of primary xenografts and metastasis formation) and, thus, determine the real
viability and efficacy of this gene therapy.
We have shown that gene inactivation of EWSR1–FLI1 using a CRISPR/Cas9 gene
editing approach resulted in a highly efficient method to utterly knockout EWSR1–FLI1 in
the Ewing sarcoma cell model A673. To our knowledge, no complete inactivation of EWSR1–
FLI1 in Ewing sarcoma cells has been reported until now. In addition, our results confirm
and extend the finding that Ewing sarcoma cells are “addicted” to EWSR1–FLI1, ratifying
the fact that targeting EWSR1–FLI1 is an excellent approach for cancer gene therapy.
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We have shown that a gRNA targeting exon 9 of FLI1, selected from a screening
performed with a multiplex CRISPR library, is able to edit EWSR1–FLI1 efficiently. Gene
editing at exon 9 of FLI1 reduced the expression of the EWSR1–FLI1 protein until un-
detectable levels and altered the expression of two well-documented EWSR1–FLI1 gene
targets (the EWSR1–FLI1-upregulated gene NR0B1 and the EWSR1–FLI1-downregulated
gene CD44). Our study in this regard is limited but suggests that total inactivation of
EWSR1–FLI1 by gene editing strengthens the expression profile induced upon EWSR1–FLI1
knockdown using shRNA strategies. Further experiments including RNAseq, ChIP-seq,
or 3C methodologies, as carried out in other studies [9,52,53], would allow deeper insight
into the dysregulated expression patterns following complete inactivation of EWSR1–FLI1.
More interestingly, EWSR1–FLI1 gene editing at exon 9 of FLI1 had a dramatic effect
on cell proliferation. Thus, gene editing totally blocked cell proliferation by resting the
cells in the G1 phase, associated with a generalized induction of cellular senescence.
We compared the effect of gene editing on protein expression, cell proliferation, and
induction of senescence with those produced in a well-established model of EWSR1–FLI1
silencing mediated by shRNAs (A673/TR/shEF cells). In all the parameters analyzed,
gene editing was significantly more effective than gene silencing, but the differences were
especially striking with regard to the inhibition of cell proliferation and induction of
cellular senescence. Senescence is a cellular state and the induction of its mechanisms
are not entirely well understood. In cancer cells, certain combinations of oncogenes,
tumor suppressor genes, hypoxia, stress, etc., can produce senescence. Even certain
stimuli can produce senescence in a certain tumor cells depending on the presence or
absence of determined mutations [54,55]. The exact mechanism that causes senescence
in A673 cells upon EWSR1–FLI1 inactivation are unknown; thus, the characterization of
these mechanisms can provide new insights into the pathogenesis of Ewing sarcoma. In
this work, we used β-galactosidase staining to identify senescent cells. Although this
is one of the most used techniques, it presents some limitations since β-galactosidase
can also accumulate in certain experimental situations such as high-density culture or
serum starvation [56–59]. However, since none of these circumstances were present in our
experiments (cells were grown under standard serum conditions (10%) and were never
allowed to reach confluence), we consider that the β-galactosidase staining assays faithfully
reflect the existence of true senescent cells.
According to our screening assay, only gRNAs targeting FLI1 exons involved in the
EWSR1–FLI1 gene showed an effect on cell viability. While these results were expected, the
screening also showed that gRNA targeting exon 9 of FLI1 was more effective than those
targeting exon 7. Although in silico approaches can potentially identify many factors that
can affect the gene editing efficiency [60,61], our results highlight the need to experimentally
validate different gRNAs to identify those that produce the highest levels of efficiency in
terms of gene editing and, therefore, more relevant from a functional point of view. Our
results also suggest that the selected gRNA had minimal, if any, off-target effects. Although
the frequency of off-targets was initially thought to be high, several recent studies have
shown that the occurrence of off-targets is actually low [62,63]. In fact, analysis of two
possible off-targets did not show any evidence of editing (Supplementary Materials, Figure
S5). Interestingly, one of these putative off-target genes corresponded to ERG, another
member of the ETS family of transcription factors involved in chromosomal translocations
in Ewing sarcomas [1]. Therefore, it is very remarkable that although FLI1 and ERG are
closely related genes, the selected FLI1 gRNA was able to discriminate between both genes
and only produce gene editing in FLI1.
Recently, it has been proposed that EWSR1–FLI1 levels in Ewing sarcoma cells can
fluctuate between a state of high expression (EWSR1–FLI1high) and a low expression one
(EWSR1–FLI1low) [53,64]. According to this hypothesis, EWSR1–FLI1high cells would
have a high proliferative index but a low capacity to disseminate. By contrast, EWSR1–
FLI1low cells would have a low proliferative index but a high capacity to disseminate.
These EWSR1–FLI1low cells would therefore be resistant to chemotherapy and potentially
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responsible for the late relapses that so frequently occur in Ewing sarcoma, usually with
fatal results. Although this hypothesis could be attractive, it must be clearly demonstrated
experimentally. In any case, this hypothesis may have important implications for therapies
that are aimed at inactivating the activity of EWSR1–FLI1, particularly if this inactivation is
only partial as is expected from pharmacological approaches, since although such drugs
were especially selective and specific, it is unlikely that they could completely block
the transcriptional activity of EWSR1–FLI1. If the inactivation of EWSR1–FLI1 is not
complete, then the use of these drugs could increase EWSR1–FLI1low cells, thus favoring
the population of cells with a propensity to metastasize. This possible problem could be
avoided if, instead of partial inactivation, a total inactivation of EWSR1–FLI1 is achieved as
that observed after EWSR1–FLI1 gene editing. In light of our results, we hypothesized that
complete inactivation of EWSR1–FLI1 in vivo would result in EWSR1–FLI1null senescent
cells that would ultimately be cleared in vivo by tissue homeostasis [65] or pharmacological
elimination [66]. Interestingly, senescent cells are capable of secreting a set of substances
(the so-called senescent secretome) that, in turn, can produce senescence in neighboring
cells [54,55,67]. We speculate that the elimination of EWSR1–FLI1 in a limited group of
tumor cells could reduce the proliferation of neighboring cells through the secretion of
pro-senescent factors, thus amplifying the effect of a possible therapy aimed at permanently
inactivating EWSR1–FLI1.
In summary, we described a gene therapy approach to targeting the EWSR1–FLI1
oncogene characteristic of Ewing sarcoma. We identified a gRNA sequence that showed a
high level of editing efficiency and specificity, producing full cycle arrest and generalized
cellular senescence. Although this strategy could be useful to target the 85% of Ewing
sarcomas harboring the EWSR1–FLI1 fusion gene, a different approach should be devel-
oped to target Ewing sarcomas with other gene fusions involving other ETS genes, such
as EWSR1-ERG (10% of cases), and even other rarer gene fusions such as EWSR1-ETV1,
EWSR1-ETV4, or EWSR1-FEV (5% of cases). A similar experimental strategy, combining
a pre-screening phase with a validation phase aimed at functionally validating the best
sgRNAs targeting these ETS genes, should provide the basic elements for developing a
gene editing therapy able to inactivate the fusion genes less frequent in Ewing sarcoma.
As with any other anti-cancer therapy, an anti-cancer gene therapy is not without
side effects. In this regard, targeting exon 9 of FLI1 could have consequences for several
cells of the hematopoietic system in which the FLI1 transcription factor plays a key role
in the differentiation of these cells [68]. Consequently, the next step on the long road to a
future clinical application of gene therapy in Ewing sarcoma is the development of a safe
strategy to transport the gene-editing machinery to the tumor cells. Although this is the
most complex point of the experimental development, the high level of research activity
that is taking place in this field allows us to have well-founded hopes for the future [69–72].
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